[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"escc\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:escc":442},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,17,0,[8,45,86,110,132,155,178,199,230,249,272,301,328,351,375,395,416],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":14,"eligibilityCriteria":15,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100640679",false,"NCT07627347","Efficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Esophageal Squamous Cell Carcinoma(ESCC)","Clinical Trial on the Efficacy and Safety of Anlotinib Combined With Bemocizumab for Neoadjuvant Therapy of Resectable Esophageal Squamous Cell Carcinoma","RAOS","Inclusion Criteria:\n\n1. Aged 18-70, both male and female\n2. After gastroscopy\u002Fultrasonic gastroscopy biopsy, the pathology suggests squamous cell carcinoma of the esophagus, and the clinical diagnosis is cT2N1-2M0 or cT3N0-2M0, with TNM staging of II-III B\n3. Patients with non-cervical esophageal cance\n4. The patient has not previously received systemic or local treatment for esophageal cancer, and according to the RECIST 1.1 criteria, there is at least one measurable lesion for imaging evaluation of neoadjuvant therapy\n5. ECOG PS: 0-1\n6. Expected survival duration ≥ 12 months\n7. The subjects had no functional disorders of major organs, and the researchers assessed that thyroid, lung, liver, kidney, and heart functions were basically normal;\n8. Women of childbearing age must have already taken reliable contraceptive measures or undergone a pregnancy test (serum or urine) within 7 days prior to enrollment, with a negative result, and be willing to use appropriate contraception during the trial and for 8 weeks after the last administration of the trial medication. For males, they must agree to use appropriate contraception during the trial and for 8 weeks after the last administration of the trial medication, or have undergone surgical sterilization\n9. The subjects voluntarily joined this study, signed the informed consent form, exhibited good compliance, actively cooperated with the planned schedule by returning to the hospital for regular clinical follow-ups and necessary treatments, and cooperated with the regular collection of blood and tissue samples\n\nExclusion Criteria:\n\n1. Within the past 5 years, there has been or is currently a co-occurrence of other malignant tumors, except for cured cervical carcinoma in situ, non-melanoma skin cancer, and superficial bladder tumors \\[Ta (non-invasive tumor), Tis (carcinoma in situ), and T1 (tumor invades the basement membrane)\\]\n2. Patients with ulcerative esophageal squamous cell carcinoma\n3. Patients with esophageal fistula or tracheal fistula;\n4. Those who are allergic to anlotinib and bemusuban\n5. Those with a history of immune deficiency, including HIV-positive or suffering from other acquired or congenital immune deficiency diseases, or those who have undergone organ transplantation\n6. Patients with any severe and\u002For uncontrolled diseases\n7. Unresolved toxic reactions above CTC AE Grade 1 caused by any previous treatment, excluding alopecia;\n8. Individuals with multiple factors affecting oral medication administration, such as inability to swallow, chronic diarrhea, and intestinal obstruction\n9. Urine routine test indicates proteinuria ≥++ and confirmed 24-hour urine protein quantitation \\> 1.0 g\n10. Subjects who underwent major surgical procedures, incisional biopsies, or significant traumatic injuries within 28 days prior to grouping\n11. Abnormal coagulation function: INR \\> 1.5 or prothrombin time (PT) \\> ULN + 4 seconds or APTT \\> 1.5ULN), with a tendency to bleed or undergoing thrombolytic or anticoagulant therapy; patients who have experienced any bleeding or hemorrhagic events ≥ CTCAE Grade 3 within 4 weeks before grouping, have unhealed wounds, ulcers, or fractures\n12. Those who have experienced arterial or venous thromboembolic events within 6 months, such as cerebrovascular accidents (including transient ischemic attacks), deep vein thrombosis, and pulmonary embolism\n13. Pregnant or lactating women\n14. Patients with distant metastasis\n15. Patients with significant bone marrow suppression\n16. Suffering from mental illness or having a history of abuse of psychotropic drugs;\n17. Patients who have participated in other drug clinical trials within 4 weeks;\n18. Patients with concomitant diseases that, according to the researcher's judgment, pose serious risks to patient safety or affect patients' ability to complete the study\n19. Individuals with hereditary bleeding tendency, coagulation dysfunction, potential invasion of large blood vessels, and other bleeding risks, who have experienced clinically significant bleeding symptoms or have a clear tendency to bleed within the previous 3 months before enrollment, such as gastrointestinal bleeding, bleeding gastric ulcer, and baseline fecal occult blood test result of ++ or above\n20. Researchers consider those who are not suitable for inclusion","ALL","18 Years","70 Years",{"count":20,"type":21},25,"ESTIMATED","INTERVENTIONAL",[24],"NA","This study aims to explore the efficacy and safety of anlotinib combined with bemocizumab as neoadjuvant therapy for resectable esophageal squamous cell carcinoma, with the goal of improving the pathological complete response (pCR) rate and margin-negative resection(R0) resection rate in patients undergoing esophageal cancer surgery, as well as enhancing disease-free survival (DFS) in postoperative patients. This will provide guidance and new options for the treatment of patients with locally advanced esophageal cancer.",[27],"ESCC",[27,29,30,31],"Neoadjuvant therapy Immunotherapy","Chemotherapy-free","Anlotinib","RECRUITING","2026-05-31",{"date":35,"type":36},"2026-06-04","ACTUAL",{"date":38,"type":36},"2026-05-18",{"date":40,"type":21},"2028-12-30",{"name":42,"class":43},"Nanfang Hospital, Southern Medical University","OTHER",1,{"id":46,"slug":4,"hasResults":10,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":55,"conditions":56,"keywords":63,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":85},"100599484","NCT07085091","A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors","A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants With Advanced or Metastatic Select Solid Tumors","Inclusion Criteria:\n\n* Participants with locally advanced, recurrent or metastatic histologically confirmed HNSCC, NSCLC, ESCC, CRC; locally advanced or recurrent disease must not be amenable to resection with curative intent\n\n  1. Dose Escalation: Participants who have relapsed or progressed following prior anticancer therapy in the advanced\u002Fmetastatic setting and for whom no approved or standard therapy is available.\n  2. Dose Exploration and Dose Expansion: The following tumor-specific criteria also apply. These cohorts will include all or a subset of these tumors.\n\nHNSCC - Received no more than 3 prior lines of therapy in the advanced or metastatic setting\n\nNSCLC - For participants with a targetable molecular alteration: received appropriate standard targeted therapy and no more than 2 prior lines of systemic chemotherapy in the advanced\u002Fmetastatic setting. For participants without a targetable molecular alteration: received platinum-based chemotherapy and CPI (in combination or separately), and have received no more than 2 prior lines of systemic chemotherapy in the advanced\u002Fmetastatic setting\n\nESCC - Received no more than 3 prior lines of therapy in the advanced\u002Fmetastatic setting\n\nCRC - For participants with a targetable molecular alteration (including dMMR or MSI-H): Received appropriate standard therapy for the alteration, at least 2 prior lines of systemic chemotherapy, and no more than 4 prior lines of therapy in the advanced\u002Fmetastatic setting. For participants without a targetable molecule alteration: Received at least 2 prior lines of systemic chemotherapy (including an oxaliplatin-based chemotherapy), vascular endothelial growth factor (VEGF)-based therapy, and no more than 4 prior lines of therapy in the advanced\u002Fmetastatic setting.\n\n* Adequate Bone Marrow Function\n* Adequate Renal \\& Liver Function\n* Adequate Performance Status\n\nExclusion Criteria:\n\n* Participants with disease suitable for local therapy with curative intent.\n* Has a life expectancy of less than 3 months and\u002For has rapidly progressing disease (e.g., tumor bleeding, uncontrolled tumor pain) in the opinion of the treating investigator\n* Prior treatment with any ADCs that have an active TOP1 inhibitor-based component",{"count":52,"type":21},170,[54],"PHASE1","A Phase 1, First in Human, Open-Label Multicenter Study to Evaluate ALX2004, an Antibody Drug Conjugate Targeting EGFR in Participants with Advanced or Metastatic Select Solid Tumors",[57,58,59,27,60,61,62],"NSCLC (Advanced Non-small Cell Lung Cancer)","HNSCC","CRC (Colorectal Cancer)","Colo-rectal Cancer","Head and Neck Cancer","Esophageal Squamous Cell Carcinoma (ESCC)",[64,65,66,67,68,69,58,70,71,72,73,74],"ALX2004","EGFR","Solid Tumors","metastatic","Antibody Drug Conjugate","ADC","CRC","Lung","Non small cell lung cancer","esophageal","EGFR ADC","2026-05-11",{"date":77,"type":36},"2026-05-12",{"date":79,"type":36},"2025-08-18",{"date":81,"type":21},"2027-12",{"name":83,"class":84},"ALX Oncology Inc.","INDUSTRY",8,{"id":87,"slug":4,"hasResults":10,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":91,"eligibilityCriteria":92,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":93,"enrollmentInfo":94,"targetDuration":4,"studyType":22,"phases":96,"briefSummary":98,"conditions":99,"keywords":4,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":4},"100638289","NCT07584031","Adebrelimab Plus Full-course Neoadjuvant Therapy for Resectable Locally Advanced ESCC (Phase 2)","A Prospective, Single-Center, Phase II Clinical Trial of Adebrelimab Combined With Full-Course Neoadjuvant Therapy for Watchful Waiting or Surgery in Patients With Resectable Locally Advanced Esophageal Squamous Cell Carcinoma","NAT-ESCC-01","Inclusion Criteria:\n\n* Patients voluntarily participate in this study, sign an informed consent form, and demonstrate good compliance;\n* At least 18 years of age; gender is not restricted;\n* ECOG performance status: 0-1;\n* Patients with histologically confirmed resectable esophageal squamous cell carcinoma clinically staged as (T1N+M0 or T2-4aNanyM0);\n* No prior anticancer therapy for esophageal cancer, including chemotherapy, hormone therapy, radiation therapy, or immunotherapy;\n* Laboratory tests must meet the following criteria (within 7 days prior to baseline enrollment):\n\n  1. Complete blood count (CBC):\n\n     1. Hemoglobin (Hb) ≥ 90 g\u002FL (no blood transfusion within the past 14 days);\n     2. Neutrophil count (NEUT) ≥ 1.5 × 10⁹\u002FL;\n     3. Platelet count (PLT) ≥ 100 × 10⁹\u002FL;\n     4. White blood cell count (WBC) ≥ 3 × 10⁹\u002FL;\n  2. Biochemical Tests:\n\n     1. Alanine transaminase (ALT) and aspartate transaminase (AST) ≤ 2.5×ULN;\n     2. Serum total bilirubin (TBIL) ≤ 1.5×ULN;\n     3. Serum creatinine (Cr) ≤ 1.5×ULN; (or creatinine clearance (CCr) ≥ 60 mL\u002Fmin);\n  3. Coagulation function: Activated partial thromboplastin time (APTT), International Normalized Ratio (INR), and prothrombin time (PT) ≤ 1.5×ULN;\n  4. Thyroid function: Thyroid-stimulating hormone (TSH) ≤ ULN (if abnormal, FT3 and FT4 levels should also be evaluated; if FT3 and FT4 levels are normal, the patient may be enrolled);\n  5. Doppler ultrasound assessment: Left ventricular ejection fraction (LVEF) ≥50%;\n* Female participants must agree to use contraceptive measures, such as an intrauterine device (IUD), oral contraceptives, or condoms, during the study and for 6 months after study completion; they must have a negative serum pregnancy test within 7 days prior to study enrollment and must not be breastfeeding; male participants must agree to use contraceptive measures during the study and for 6 months after study completion.\n\nExclusion Criteria:\n\n* Concurrent malignant neoplasms (except for cured basal cell carcinoma of the skin);\n* Diagnosis of cervical esophageal cancer;\n* History of severe hypersensitivity reactions following administration of other monoclonal antibodies;\n* Presence of any active autoimmune disease or history of autoimmune disease (such as, but not limited to: autoimmune hepatitis, interstitial pneumonia, enteritis, vasculitis, or nephritis; asthma requiring bronchodilators for medical intervention); however, the following patients are eligible for enrollment: vitiligo, psoriasis, or alopecia not requiring systemic treatment; well-controlled type 1 diabetes; hypothyroidism with normal thyroid function following replacement therapy;\n* Requiring immunosuppressants, or systemic or absorbable topical corticosteroids for immunosuppressive purposes (dose \\> 10 mg\u002Fday of prednisone or other corticosteroids of equivalent potency), and still using them within 2 weeks of the first dose;\n* Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage;\n* Uncontrolled symptoms of brain metastases, spinal cord compression, or carcinomatous meningitis occurring within 4 weeks prior to the first dose, or patients with brain or meningeal disease identified by CT or MRI at screening;\n* Patients with any severe and\u002For uncontrolled medical conditions, including:\n\n  1. Acute or recurrent myocardial ischemia or myocardial infarction; poorly controlled and clinically significant arrhythmias; and heart failure of Class II or higher (New York Heart Association \\[NYHA\\] functional class); LVEF (left ventricular ejection fraction) \\\u003C 50%;\n  2. Active or uncontrolled severe infection (≥ Grade 2 CTC AE infection);\n* Receipt of a prophylactic or attenuated vaccine within 4 weeks prior to the first dose;\n* Other factors, as determined by the investigator, that may lead to forced discontinuation of the study, such as other serious illnesses (including psychiatric disorders) requiring concomitant treatment, severe laboratory abnormalities, or family or social factors that could compromise the subject's safety.\n* If HBsAg (+) and\u002For HBcAb (+), HBV DNA must be \\\u003C 500 IU\u002FmL (if the local center's lower limit of detection is higher than 500 IU\u002FmL, the investigator may decide on enrollment based on specific circumstances) and the subject must continue to receive effective anti-HBV therapy during the study, or must have already started treatment with entecavir or tenofovir prior to study drug administration;\n* If HCV antibodies are positive, HCV-RNA testing must be performed; subjects with HCV-RNA \\> 10³ copies\u002FmL must be excluded;\n* HIV-positive.","75 Years",{"count":95,"type":21},200,[97],"PHASE2","This is a prospective, single-center, randomized phase 2 study of adebrelimab plus full-course neoadjuvant therapy in resectable locally advanced esophageal squamous cell carcinoma. Patients achieving clinical complete response (cCR) after neoadjuvant treatment will be randomized 1:1 to watchful waiting with 2 cycles consolidation chemo-Immunotherapy or standard surgery. Primary endpoint is 2-year DFS. Secondary endpoints include OS, pCR\u002FMPR, R0 resection rate, safety, and quality of life.",[27],"NOT_YET_RECRUITING","2026-05-07",{"date":103,"type":36},"2026-05-13",{"date":105,"type":21},"2026-06-01",{"date":107,"type":21},"2028-12-31",{"name":109,"class":43},"Tianjin Medical University Cancer Institute and Hospital",{"id":111,"slug":4,"hasResults":10,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":93,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":4},"100633947","NCT07533305","Efficacy and Safety of QL1706 Combined With Nab-paclitaxel and Cisplatin as 1st Line Therapy for Advanced or Metastatic Esophageal Squamous Cell Carcinoma","A Single-arm Clinical Study of QL1706 (Anti PD-1 and CTLA-4 Antibody) in Combination With Nab-paclitaxel and Cisplatin as First-line Therapy in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma","Inclusion Criteria:\n\n* Subjects participate voluntarily and sign informed consent.\n* 18-75 years, male or female.\n* Histologically confirmed Unresectable Advanced or metastatic Esophageal Squamous Cell Carcinomas\n* No previous systemic anti-tumor treatment for unresectable locally advanced or metastatic esophageal squamous cell carcinoma has been received\n* At least 1 measurable target lesion and\u002For unmeasurable target lesion according to Response Evaluation in Solid Tumors (RECIST 1.1).\n* ECOG PS 0-1\n* Expected survival ≥ 12 weeks\n* Adequate organ function (without blood transfusion or growth factors within 14 days prior to first dose), including: ANC ≥ 1.5 × 10⁹\u002FL; Platelets ≥ 100 × 10⁹\u002FL; Hemoglobin ≥ 90 g\u002FL; Serum albumin ≥ 30 g\u002FL; Total bilirubin ≤ 1.5 × ULN; ALT\u002FAST ≤ 2.5 × ULN (≤ 5 × ULN if with liver or bone metastases); ALP ≤ 2.5 × ULN; Serum creatinine ≤ 1.5 × ULN; INR ≤ 1.5 (if not on anticoagulation);\n* Non-sterilized women of childbearing potential and male participants with such partners must agree to use medically approved contraception during and for 3 months after study drug administration. Women must test negative for serum or urine HCG within 7 days prior to first dose and not be breastfeeding\n\nExclusion Criteria:\n\n* Have received anti-PD-1 or anti-PD-L1 antibody therapy;\n* BMI \\\u003C 18.5 kg\u002Fm2 or weight loss ≥ 10% within 2 months before screening (at the same time, the effect of a large amount of pleural effusions and ascites on bogy weight should be considered);\n* Presence of any active autoimmune disease or history of autoimmune disease (such as: Autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hypophysitis, nephritis, hyperthyroidism)\n* Those who are taking immunosuppressants or systemic hormonal therapy for immunosuppressive purposes (dose\\> 10 mg\u002Fday prednisone or other equivalent cortiremonial hormones)\n* Severe allergic reaction to other monoclonal antibodies\n* Known history or evidence of interstitial lung disease or active non-infectious pneumonia\n* Known central nervous system metastases\n* History of other malignancies within the past 5 years or concurrent malignancies (except for cured basal cell carcinoma of the skin and carcinoma in situ of the cervix).\n* Uncontrolled cardiac clinical symptoms or diseases, such as: (1) NYHA class II or higher heart failure (2) unstable angina (3) myocardial infarction within the past year (4) clinically significant supraventricular or ventricular arrhythmias requiring treatment or intervention (5) QTc \\> 450 ms (male); QTc \\> 470 ms (female)\n* Tumor invasion of major blood vessels, or based on imaging, the investigator determines a high likelihood of tumor invasion of major blood vessels during the study period, which may lead to fatal bleeding, such as imaging evidence of \\>90-degree encasement of major vessels or tumor cavitation\n* Patients with pleural effusion, ascites, or pericardial effusion requiring drainage; if the symptoms are stable after drainage as assessed by the investigator, enrollment is possible. Gastrointestinal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to the start of study treatment.\n* Major surgical procedures within 4 weeks prior to the start of study treatment (diagnostic procedures excluded) or anticipated need for major surgery during the study period.\n* Active infection, unexplained fever ≥38.5°C within 7 days prior to drug administration, or baseline white blood cell count \\>15×109\u002FL.\n* Congenital or acquired immunodeficiency (e.g., HIV infection); hepatitis B surface antigen (HBsAg) positive with hepatitis B virus deoxyribonucleic acid (HBV DNA) ≥2000 IU\u002Fml, or positive for hepatitis C virus antibody.\n* Live vaccine administration within 4 weeks prior to study drug administration or during the study period.\n* As judged by the investigator, other factors that may affect study outcomes or lead to premature termination of the study, such as alcoholism, drug abuse, other serious diseases (including psychiatric disorders) requiring concurrent treatment, significant laboratory abnormalities, or family or social factors that may impact patient safety.",{"count":117,"type":21},50,[97],"The purpose of this study is to assess the efficacy and safety of QL1706 combined with nab-paclitaxel and cisplatin in first-line therapy for patients with advanced or metastatic esophageal squamous cell carcinoma. QL1706 is a anti-PD-1 and anti-CTLA4 antibody.",[121,27,122],"QL1706","First-line Therapy","2026-04-14",{"date":125,"type":36},"2026-04-16",{"date":127,"type":21},"2026-05-01",{"date":129,"type":21},"2029-06-30",{"name":131,"class":43},"The First Affiliated Hospital of Henan University of Science and Technology",{"id":133,"slug":4,"hasResults":10,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":138,"targetDuration":4,"studyType":22,"phases":140,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":44},"100633845","NCT07531979","Prospective, Open-label, Multi-cohort Study of Becotatug Vedotin With Tislelizumab and Chemotherapy in Esophageal Squamous Cell Carcinoma - Phase 2","A Prospective, Open-label, Multicohort, Phase II Clinical Study of Becotatug Vedotin in Combination With Tislelizumab and Chemotherapy for Esophageal Squamous Cell Carcinoma","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Male or non-pregnant, non-lactating female.\n3. ECOG performance status of 0 or 1, with no deterioration within 7 days.\n4. Histologically confirmed locally advanced or metastatic esophageal squamous cell carcinoma.\n5. No prior systemic therapy for ESCC. Patients who have received neoadjuvant or adjuvant therapy must have experienced disease progression or recurrence more than 6 months after completion of that treatment.\n6. Patients with metastatic disease must have at least one measurable lesion per RECIST 1.1 criteria; patients with disease after neoadjuvant therapy must have an evaluable lesion.\n7. Adequate organ and bone marrow function, as demonstrated by the following laboratory values:\n\n   1. Hemoglobin (HGB) ≥ 90 g\u002FL.\n   2. Absolute neutrophil count (NEUT) ≥ 1.5 × 10⁹\u002FL.\n   3. Platelet count (PLT) ≥ 80 × 10⁹\u002FL.\n   4. Total bilirubin (TBIL) ≤ 1.5 × the upper limit of normal (ULN).\n   5. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN; for patients with liver metastases, ALT and AST ≤ 5 × ULN.\n   6. Creatinine clearance ≥ 50 mL\u002Fmin (calculated by the Cockcroft-Gault formula).\n   7. Urine protein \\\u003C (++) or 24-hour urinary protein \\\u003C 1.0 g.\n8. Normal coagulation function and no active bleeding:\n\n   1. International Normalized Ratio (INR) ≤ 1.5.\n   2. Activated Partial Thromboplastin Time (APTT) ≤ 1.5 × ULN.\n9. For women of childbearing potential: negative pregnancy test (serum or urine) within 14 days prior to enrollment, and agreement to use adequate contraception during the study period and for 8 weeks after the last dose of study drug. For men: surgically sterile or agreement to use adequate contraception during the study period and for 8 weeks after the last dose of study drug.\n10. Expected survival ≥ 6 months.\n11. Patient voluntarily participates in the study and signs the informed consent form (ICF).\n12. Patient is expected to be compliant and able to undergo follow-up for efficacy and adverse events as required by the protocol.\n\nExclusion Criteria:\n\nPatients meeting any of the following criteria at screening will be excluded from the study:\n\n1. Prior treatment with any anti-EGFR monoclonal antibody, or with anti-PD-1\u002FPD-L1 antibody, anti-PD-L2 antibody, anti-CD137 antibody, CTLA-4 antibody, or any other drug\u002Fantibody targeting T-cell co-stimulation or checkpoint pathways.\n2. Administration of a live vaccine within 4 weeks prior to enrollment or anticipated during the study period.\n3. Active autoimmune disease or a history of autoimmune disease within 4 weeks prior to enrollment.\n4. Prior allogeneic bone marrow transplantation or solid organ transplant.\n5. Uncontrolled hypertension at enrollment, defined as: systolic blood pressure ≥ 160 mmHg and\u002For diastolic blood pressure ≥ 90 mmHg.\n6. Any disease or condition affecting drug absorption at enrollment.\n7. Clinically significant cardiovascular disease, including but not limited to: acute myocardial infarction within 6 months prior to enrollment; severe\u002Funstable angina or coronary artery bypass grafting; congestive heart failure \\> New York Heart Association (NYHA) Class 2; ventricular arrhythmias requiring medication; left ventricular ejection fraction (LVEF) \\\u003C 50%.\n8. Active or uncontrolled severe infection (≥ CTCAE v5.0 Grade 2 infection).\n9. Known HIV infection. Known clinically significant liver disease, including viral hepatitis \\[known hepatitis B virus (HBV) carriers must be excluded if they have active HBV infection, i.e., HBV DNA positive (\\>1×10⁴ copies\u002FmL or \\>2000 IU\u002FmL); known hepatitis C virus (HCV) infection with HCV RNA positive (\\>1×10³ copies\u002FmL)\\].\n10. Any other disease, clinically significant metabolic abnormality, physical examination finding, or laboratory abnormality that, in the investigator's judgment, reasonably suggests the presence of a disease or condition that contraindicates the use of the investigational drug (e.g., a condition associated with seizures requiring treatment), would affect the interpretation of study results, or would place the patient at high risk.\n11. Patients deemed by the investigator to be unsuitable for participation in this study.",{"count":139,"type":21},93,[97],"Esophageal squamous cell carcinoma (ESCC) is a common malignant tumor worldwide, with particularly high incidence in East Asian regions such as China, and is associated with poor patient prognosis. In recent years, immune checkpoint inhibitors (e.g., anti-PD-1\u002FPD-L1 antibodies) combined with chemotherapy have become the standard first-line treatment for advanced ESCC. Multiple randomized controlled trials have confirmed that this combination significantly improves patient survival compared to chemotherapy alone. However, a subset of patients still exhibit poor response or develop resistance to the immunotherapy-chemotherapy regimen, necessitating the exploration of novel combination strategies to further enhance efficacy.\n\nThe epidermal growth factor receptor (EGFR) is frequently overexpressed in ESCC and is associated with tumor proliferation, metastasis, and poor prognosis, making it an important therapeutic target. Antibody-drug conjugates (ADCs) targeting EGFR achieve precise tumor killing by conjugating an anti-EGFR antibody to a potent cytotoxic payload. Preclinical studies have demonstrated significant antitumor activity of EGFR ADCs in ESCC models. Mechanistically, anti-EGFR therapy and immune checkpoint inhibitor therapy may exert synergistic effects through several avenues: enhancing tumor antigen presentation, remodeling the tumor microenvironment, and modulating PD-L1 expression. Therefore, this triple combination strategy holds promise for overcoming the limitations of monotherapies and providing a new treatment option for patients with ESCC.",[27,143,144,145,74,146],"Tislelizumab","Chemotherapy","Becotatug Vedotin","PD-1 Inhibitor","2026-04-13",{"date":149,"type":36},"2026-04-15",{"date":151,"type":21},"2026-04-01",{"date":153,"type":21},"2029-12-31",{"name":109,"class":43},{"id":156,"slug":4,"hasResults":10,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":4,"eligibilityCriteria":160,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":161,"targetDuration":4,"studyType":22,"phases":163,"briefSummary":164,"conditions":165,"keywords":166,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":170,"lastUpdatePostDateStruct":171,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":44},"100633260","NCT07524374","SHR-1701 in Combination With Irinotecan Liposome (II) for Second-line Treatment of ESCC After Immunotherapy","The Efficacy, Safety and Feasibility of SHR-1701 in Combination With Irinotecan Liposome (II) for Second-line Treatment of Esophageal Squamous Cell Carcinoma After Immunotherapy","Inclusion Criteria:\n\n1. Signed written informed consent, voluntarily participating in this study;\n2. Histopathologically or cytologically confirmed esophageal squamous cell carcinoma;\n3. Prior treatment with immunotherapy;\n4. At least one measurable lesion as assessed by RECIST version 1.1;\n5. Age ≥ 18 years, male or female;\n6. ECOG performance status of 0 or 1;\n7. Life expectancy \\> 3 months;\n8. Adequate organ function:\n\n   1. Hematology: Neutrophils ≥ 1.5 × 10\\^9\u002FL, Hemoglobin ≥ 9 g\u002FdL, Platelets ≥ 100 × 10\\^9\u002FL.\n   2. Hepatic function: Bilirubin ≤ 1.5 × the upper limit of normal (ULN) (patients with known Gilbert's disease and serum bilirubin ≤ 3 × ULN are eligible); AST and ALT ≤ 2.5 × ULN (if liver metastases are present, AST\u002FALT ≤ 5 × ULN); Alkaline phosphatase ≤ 3 × ULN (if liver or bone metastases are present, ALP ≤ 5 × ULN); Albumin ≥ 3 g\u002FdL.\n   3. Renal function: Serum creatinine ≤ 1.5 × ULN or estimated glomerular filtration rate by Cockcroft-Gault: Creatinine clearance ≥ 60 mL\u002Fmin.\n   4. Coagulation function: International normalized ratio (INR) ≤ 1.5 × ULN; Activated partial thromboplastin time (APTT) ≤ 1.5 × ULN.\n9. Female patients of childbearing potential must have a negative serum pregnancy test within 72 hours prior to the first dose, must not be breastfeeding, and must agree to use effective contraception for 6 months after the last dose; for male patients with a partner of childbearing potential, effective contraception must be used for 3 months after the last dose; sperm donation is not permitted during the study;\n10. Patients are well compliant and agree to cooperate with follow-up.\n\nExclusion Criteria:\n\n* 1\\. Active or untreated central nervous system (CNS) metastases (e.g., brain or leptomeningeal metastases) as determined by CT or magnetic resonance imaging (MRI) assessment during screening.\n\n  2\\. Uncontrolled tumor-related pain. 3. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring repeated drainage (once a month or more frequently); patients with an indwelling catheter (e.g., PleurX®) are permitted.\n\n  4\\. History of a malignancy other than esophageal cancer within 5 years prior to enrollment, except for malignancies with a negligible risk of metastasis or death (e.g., expected 5-year overall survival \\> 90%) and those that are expected to be cured after treatment.\n\n  5\\. History of allergy to monoclonal antibodies, liposomal products, or irinotecan.\n\n  6\\. Prior or current receipt of any of the following therapies:\n  1. Use of immunosuppressive medications or systemic corticosteroid therapy for immunosuppressive purposes (dose \\> 10 mg\u002Fday prednisone or equivalent) within 2 weeks prior to the first dose of study drug; inhaled or topical steroids and adrenal corticosteroid replacement at doses \\> 10 mg\u002Fday prednisone or equivalent are permitted in the absence of active autoimmune disease.\n  2. Receipt of a live attenuated vaccine within 4 weeks prior to the first dose of study drug.\n  3. Major surgery or significant traumatic injury within 4 weeks prior to the first dose of study drug.\n\n     7\\. Any active autoimmune disease or a history of autoimmune disease. 8. History of immunodeficiency, including a positive HIV test, or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation or allogeneic bone marrow transplantation.\n\n     9\\. Presence of poorly controlled cardiac clinical symptoms or diseases. 10. Occurrence of a severe infection within 4 weeks prior to the first dose of study drug.\n\n     11\\. Active pulmonary tuberculosis infection as identified by medical history or CT examination.\n\n     12\\. Active hepatitis B (HBV DNA ≥ 200 IU\u002FmL or ≥ 1000 copies\u002FmL or ≥ the upper limit of normal), or hepatitis C (positive hepatitis C antibody and HCV RNA above the lower limit of quantification of the assay).\n\n     13\\. Pregnant or breastfeeding women. 14. Any other condition judged by the investigator that could lead to forced discontinuation from the study, such as other serious illnesses (including mental illnesses) requiring concomitant treatment, alcoholism, drug abuse, family or social factors, or factors that could affect patient safety or compliance.",{"count":162,"type":21},33,[97],"This study is a single-arm, exploratory clinical trial aimed at evaluating the efficacy and safety of SHR-1701 in combination with liposomal irinotecan (II) in patients with esophageal squamous cell carcinoma who have received prior immunotherapy. Eligible patients with esophageal cancer will be treated with SHR-1701 in combination with liposomal irinotecan (II).",[27],[27,167,168,169],"SHR-1701","Retlirafusp alfa","Liposomal Irinotecan (II)","2026-04-06",{"date":147,"type":36},{"date":173,"type":21},"2026-03-15",{"date":175,"type":21},"2028-03-30",{"name":177,"class":43},"Zhigang Li",{"id":179,"slug":4,"hasResults":10,"nctId":180,"briefTitle":181,"officialTitle":181,"acronym":4,"eligibilityCriteria":182,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":183,"targetDuration":4,"studyType":22,"phases":185,"briefSummary":186,"conditions":187,"keywords":188,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":196,"leadSponsor":198,"locationsCount":44},"100630924","NCT07493993","Clinical Study on the Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Nab-Paclitaxel in Neoadjuvant Therapy for Locally Advanced Resectable Esophageal Squamous Cell Carcinoma","Inclusion Criteria:\n\n* Voluntarily understand and sign the informed consent form for this study.\n* Age ≥ 18 years, male or female.\n* Histologically or cytologically confirmed thoracic ESCC (Stage T1-2N1-2M0 or T3N0-2M0, according to the AJCC 8th edition).\n* ECOG performance status of 0-2.\n* No prior treatment for esophageal squamous cell carcinoma.\n* Life expectancy ≥ 3 months.\n* Adequate function of major organs within 7 days before the first treatment (use of any blood components or cell growth factors within 14 days before enrollment is not permitted):Hemoglobin ≥ 90 g\u002FL; White blood cell count ≥ 3.5 × 10\\^9\u002FL; Absolute neutrophil count ≥ 1.5 × 10\\^9\u002FL; Platelets ≥ 80 × 10\\^9\u002FL; AST and ALT ≤ 2.5 × ULN; Total bilirubin (TBIL) ≤ 1.5 × ULN; Blood urea nitrogen (BUN) and creatinine (Cr) ≤ 1.5 × ULN (and creatinine clearance (CCr) ≥ 50 mL\u002Fmin); Left ventricular ejection fraction (LVEF) ≥ 50%.\n* Fertile patients must agree to use reliable contraceptive methods with their partner during the trial and for at least 180 days after the last dose.\n\nExclusion Criteria:\n\n* Inability to comply with the study protocol or study procedures.\n* Presence of supraclavicular lymph node metastasis.\n* Obvious tumor invasion of organs adjacent to the esophageal lesion.\n* Evidence of esophagomediastinal or tracheoesophageal fistula found on imaging within 4 weeks before enrollment.\n* Allergy or known hypersensitivity to the study drugs or their excipients.\n* Anticipated need for systemic corticosteroids or other immunosuppressive therapy during the study treatment period.\n* Active autoimmune disease requiring systemic treatment, or a history of autoimmune disease.\n* Positive HIV test; positive hepatitis B surface antigen with HBV-DNA \\> upper limit of normal; active hepatitis C virus (HCV) infection.\n* History of esophageal or gastric variceal bleeding due to portal hypertension within 6 months before the first study drug administration; known severe varices on endoscopy within 3 months before the first study drug administration.\n* Current interstitial pneumonia or interstitial lung disease, or a history of interstitial pneumonia or interstitial lung disease requiring steroid therapy, or other pulmonary fibrosis, organizing pneumonia that might interfere with the assessment and management of immune-related pulmonary toxicity.\n* Evidence of a significant bleeding tendency or other major coagulation disorders.\n* Severe cardiovascular or cerebrovascular disease.\n* Other malignancies within 5 years before enrollment, except for radically resected basal cell or squamous cell carcinoma of the skin, or carcinoma in situ of the cervix.\n* History of allogeneic bone marrow transplantation or organ transplantation.\n* Patients considered by the investigator to be unsuitable for participation in this study.",{"count":184,"type":21},26,[97],"Major objectives to evaluate the efficacy and safety of Iparomlimab and Tuvonralimab Injection (QL1706,an Anti-PD-1\u002FCTLA-4 Combined Antibody) combined with Nab-Paclitaxel in neoadjuvant therapy for patients with locally advanced resectable esophageal squamous cell carcinoma.",[27],[189,190,191,27],"Iparomlimab and Tuvonralimab Injection","Nab-Paclitaxel","neoadjuvant therapy","2026-03-19",{"date":194,"type":36},"2026-03-27",{"date":105,"type":21},{"date":197,"type":21},"2030-12-31",{"name":109,"class":43},{"id":200,"slug":4,"hasResults":10,"nctId":201,"briefTitle":202,"officialTitle":203,"acronym":4,"eligibilityCriteria":204,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":205,"targetDuration":4,"studyType":22,"phases":207,"briefSummary":208,"conditions":209,"keywords":218,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":220,"lastUpdatePostDateStruct":221,"startDateStruct":223,"completionDateStruct":225,"leadSponsor":227,"locationsCount":229},"100606945","NCT07182149","A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors","A Phase 1a\u002F1b Study of NRM-823 as Monotherapy and in Combination With Immune Checkpoint Inhibition in Participants With Locally Advanced or Metastatic Refractory Solid Tumors","Inclusion Criteria:\n\n* Have histologically- or cytologically-diagnosed NSCLC (squamous or adenocarcinoma), TNBC, HNSCC, ESCC, esophageal adenocarcinoma, gastric\u002FGEJ adenocarcinoma, cervical, endometrial, or ovarian cancer which is advanced or metastatic.\n* Have an Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.\n* Adequate liver, renal, pulmonary, and cardiac function.\n* Adequate hematologic function.\n\nExclusion Criteria:\n\n* Has received cytotoxic chemotherapy, biologic anticancer agents, checkpoint inhibitors, or radiation therapy (excluding bone-only radiation therapy) ≤3 weeks or 5 half-lives (whichever is shorter) prior to the first dose of NRM-823\n* History of Grade 2 pneumonitis requiring steroids or any Grade 3 or 4 pneumonitis from any prior therapy.\n* Has received an investigational therapy \\\u003C4 weeks or 5 half-lives prior to the first dose of NRM823, whichever is shorter prior to the first dose of NRM-823.\n* With the exception of alopecia and Grade ≤2 neuropathy, any unresolved toxicities from prior therapy greater than CTCAE Grade 1 at the time of starting study drug.",{"count":206,"type":21},150,[54],"This study is being done to find out of NRM-823 is safe and can treat participants with locally advanced or metastatic solid tumors.",[58,27,210,211,212,213,214,215,216,217],"Esophageal Adenocarcinoma","Gastric Adenocarcinoma","GEJ Adenocarcinoma","Ovarian Cancer","NSCLC","Cervical Cancer","Endometrial Cancer","Triple Negative Breast Cancer (TNBC)",[219],"NRM-823","2026-02-10",{"date":222,"type":36},"2026-02-12",{"date":224,"type":36},"2025-10-30",{"date":226,"type":21},"2028-10-31",{"name":228,"class":84},"Normunity AccelCo, Inc.",9,{"id":231,"slug":4,"hasResults":10,"nctId":232,"briefTitle":233,"officialTitle":234,"acronym":4,"eligibilityCriteria":235,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":93,"enrollmentInfo":236,"targetDuration":4,"studyType":22,"phases":238,"briefSummary":239,"conditions":240,"keywords":4,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":241,"lastUpdatePostDateStruct":242,"startDateStruct":244,"completionDateStruct":246,"leadSponsor":248,"locationsCount":4},"100622782","NCT07388095","Adebrelimab Neoadjuvant Treatment for Resectable ESCC","Neoadjuvant Treatment With Adebrelimab in Combination With Nimotuzumab and Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma: A Single-arm, Exploratory Phase II Clinical Study","Inclusion Criteria:\n\n1. Signed written informed consent to voluntarily participate in this study;\n2. Pathologically confirmed resectable esophageal squamous cell carcinoma (excluding mixed adenocarcinoma-squamous cell carcinoma types);\n3. Thoracic esophageal cancer confirmed by CT\u002FMRI\u002FEUS assessment with clinical stage IIA-IIIB (according to AJCC 8th edition);\n4. Age 18-75 years, male or female;\n5. ECOG PS 0-1;\n6. No prior anticancer treatment for esophageal cancer, including radiotherapy, chemotherapy, or surgery;\n7. Planned surgical treatment following completion of neoadjuvant therapy;\n8. No surgical contraindications;\n9. Normal major organ function, including: (1) Complete blood count (no use of blood components, cell growth factors, leukocyte-stimulating agents, platelet-stimulating agents, or anemia-correcting agents within 14 days prior to first study drug administration): White blood cell count ≥ 4.0 × 10\\^9\u002FL Neutrophil count ≥ 1.5 × 10\\^9\u002FL Platelet count ≥ 90 × 10\\^9\u002FL Hemoglobin ≥ 90 g\u002FL (2) Blood Biochemistry Tests: Total Bilirubin ≤ 1.5×ULN, LT ≤ 2.5×ULN, AST ≤ 2.5×ULN, Serum Creatinine ≤ 1.5×ULN, or Creatinine Clearance ≥ 50 mL\u002Fmin (Cockcroft-Gault formula) c) Coagulation Function: International Normalized Ratio (INR) ≤ 1.5×ULN Activated Partial Thromboplastin Time (APTT) ≤ 1.5×ULN\n10. Female subjects of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to initiation of study drug administration and must use effective contraception (e.g., intrauterine device, oral contraceptives, or condoms) during the trial and for at least 3 months after the last dose. Male subjects with female partners of childbearing potential must use effective contraception during the trial and for 3 months after the last dose;\n11. Subjects must demonstrate good compliance and willingness to participate in follow-up.\n\nExclusion Criteria:\n\n1. Tumor has significantly invaded adjacent organs (major arteries or trachea) near the esophageal lesion;\n2. Presence of supraclavicular lymph node metastasis;\n3. Presence of uncontrollable pleural effusion, pericardial effusion, or ascites requiring repeated drainage;\n4. Malnutrition with BMI \\\u003C 18.5 kg\u002Fm²; if corrected by symptomatic nutritional support prior to enrollment and approved by the principal investigator, enrollment may still be considered;\n5. History of allergy to monoclonal antibodies, any component of adebrelimab, any component of Nimotuzumab, albumin-bound paclitaxel, cisplatin, or other platinum-based drugs;\n6. Prior or current treatment with any of the following: (1) Any radiation therapy, chemotherapy, or other anti-neoplastic agents directed at the tumor; (2) Use of immunosuppressive agents or systemic corticosteroids for immunosuppression (dose \\>10 mg\u002Fday prednisone or equivalent) within 2 weeks prior to first study drug administration; Inhaled or topical steroids and corticosteroid replacement therapy at a dose \\>10 mg\u002Fday of prednisone or equivalent are permitted in the absence of active autoimmune disease; (3) Received a live attenuated vaccine within 4 weeks prior to the first dose of study drug; (4) Undergone major surgery or sustained severe trauma within 4 weeks prior to the first dose of study drug;\n7. Presence of any active autoimmune disease or history of autoimmune disease, including but not limited to: interstitial pneumonia, enteritis, hepatitis, hypophysitis, vasculitis, nephritis, hyperthyroidism, hypothyroidism (may be considered for inclusion after hormone replacement therapy); Individuals with psoriasis or childhood asthma\u002Fallergies that have achieved complete remission and require no intervention in adulthood may be considered for inclusion; however, patients requiring medical intervention with bronchodilators are excluded;\n8. History of immunodeficiency, including HIV-positive status, or other acquired or congenital immunodeficiency disorders, or history of organ transplantation or allogeneic bone marrow transplantation;\n9. Uncontrolled cardiac clinical symptoms or disease, including but not limited to: (1) NYHA Class II or higher heart failure, (2) unstable angina, (3) myocardial infarction within the past year, (4) clinically significant supraventricular or ventricular arrhythmias uncontrolled despite clinical intervention or with poor control after intervention;\n10. Severe infection (CTCAE ≥ Grade 2) within 4 weeks prior to first study drug administration, such as severe pneumonia requiring hospitalization, bacteremia, or infection-related complications; exclusion if baseline chest imaging indicates active pulmonary inflammation, or if symptoms\u002Fsigns of infection or need for oral\u002FIV antibiotics exist within 14 days prior to first study drug administration (excluding prophylactic antibiotic use);\n11. Active pulmonary tuberculosis infection identified through medical history or CT examination; history of active pulmonary tuberculosis infection within 1 year prior to enrollment; or history of active pulmonary tuberculosis infection more than 1 year prior without formal treatment;\n12. Active hepatitis B (HBV DNA ≥ 2000 IU\u002FmL or 10\\^4 copies\u002FmL) or hepatitis C (HCV antibody positive with HCV RNA above the lower limit of detection of the assay method);\n13. Imaging demonstrating tumor invasion into the perivascular space of a major vessel, or patients judged by the investigator to be at high risk of fatal hemorrhage due to tumor invasion into a major vessel during the study period;\n14. Patients diagnosed with other malignancies within 5 years prior to first administration of the study drug, unless the malignancy carries a low risk of metastasis or mortality (5-year survival rate \\> 90%), such as adequately treated basal cell carcinoma, squamous cell carcinoma of the skin, or cervical carcinoma in situ, which may be considered for inclusion;\n15. Patients with uncontrolled hypertension despite antihypertensive therapy (systolic blood pressure ≥150 mmHg or diastolic blood pressure ≥100 mmHg); or patients requiring two or more antihypertensive agents to control blood pressure; patients with a history of hypertensive crisis or hypertensive encephalopathy;\n16. Pregnant or lactating women;\n17. Other factors deemed by the investigator to potentially necessitate premature study discontinuation, such as concomitant treatment for other serious illnesses (including psychiatric disorders), alcohol abuse, substance misuse, or familial\u002Fsocial factors that may compromise subject safety or compliance.\n18. Other circumstances deemed unsuitable for inclusion by the investigator.",{"count":237,"type":21},22,[24],"This is a prospective, phase II, exploratory clinical trial.\n\nThe study aims to evaluate the efficacy and safety of in combination adebrelimab with nimotuzumab and chemotherapy as neoadjuvant therapy in patients with resectable esophageal squamous cell carcinoma.\n\nThe primary endpoint is pCR ( pathological complete response), evaluating the efficacy of adebrelimab in combination with nimotuzumab and neoadjuvant chemotherapy in patients with resectable esophageal squamous cell carcinoma. After the primary objective is achieved, EFS (event free survival ), R0 resection rate, MPR (major pathological response), OS (overall survival), and safety will be assessed as key secondary objectives. The study plans to enroll 22 patients with resectable esophageal squamous cell carcinoma.\n\nThe study is divided into a screening period, a treatment period, and a follow-up period. Subjects will enter the screening period after signing informed consent. Subjects who pass the screening assessment will be enrolled in the study. Eligible subjects will receive two cycles of neoadjuvant therapy with adebrelimab, nimotuzumab, nab-paclitaxel, and cisplatin. Esophagectomy will be performed after two cycles of neoadjuvant therapy (4-6 weeks after the last dose). Researchers will determine subsequent treatment based on postoperative pathology. After treatment (surgery), safety and efficacy follow-ups will commence. When a subject first experiences disease progression as assessed by the investigator according to RECIST v1.1, confirmation is required after 4-6 weeks (except for rapid or significant clinical progression). Subjects whose disease progression is not confirmed by imaging after 4-6 weeks may continue treatment if their clinical symptoms remain stable, as determined by the investigator, until imaging-confirmed disease progression occurs, or other termination criteria as specified in the protocol are met, whichever occurs first.",[27],"2026-01-30",{"date":243,"type":36},"2026-02-04",{"date":245,"type":21},"2026-02-15",{"date":247,"type":21},"2028-02-28",{"name":109,"class":43},{"id":250,"slug":4,"hasResults":10,"nctId":251,"briefTitle":252,"officialTitle":253,"acronym":254,"eligibilityCriteria":255,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":93,"enrollmentInfo":256,"targetDuration":4,"studyType":22,"phases":257,"briefSummary":258,"conditions":259,"keywords":262,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":263,"lastUpdatePostDateStruct":264,"startDateStruct":266,"completionDateStruct":268,"leadSponsor":270,"locationsCount":44},"100574828","NCT06764355","Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced Esophageal Squamous Cell Carcinoma","Total Neoadjuvant Therapy With Induction Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Locally Advanced Esophageal Squamous Cell Carcinoma","NICE-ESCC","Inclusion Criteria:\n\n1. Pathologically proven squamous cell carcinoma of the intrathoracic esophagus.\n2. Locally advanced disease, which is defined by the TNM system of the American Joint Committee on Cancer (AJCC) Cancer Staging System (8th edition), fulfilling one of the following criteria as determined by staging procedures (including but not limited to endoscopic ultrasound, computed tomography, bronchoscopy or positron emission tomography):\n\n   1. cT3\u002F4a, N0, M0;\n   2. cT1-4a, N1-3, M0.\n3. Tumor length longitudinal ≤ 10cm and radial ≤ 5cm.\n4. The tumor must not extend more than 2cm into the stomach.\n5. No invasion of the tracheobronchial tree or presence of tracheoesophageal fistula.\n6. Age ≥ 18 and ≤ 75 years old.\n7. Performance status ECOG 0\\~1.\n8. Adequate bone marrow reserves, defined as:\n\n   1. white blood cells (WBC) ≥ 3,000\u002Fµl or neutrophil count (ANC) ≥ 1,500\u002Fµl;\n   2. platelets ≥ 100,000\u002Fµl.\n9. Adequate liver function reserves, defined as:\n\n   1. hepatic transaminases ≤ 2.5 x upper limit of normal (ULN);\n   2. serum total bilirubin ≤ 2.0 x upper limit of normal (ULN).\n10. Adequate renal function: Creatinine ≤1.5 x upper normal limit or estimated creatinine clearance ≥ 50 ml\u002Fmin (estimated by Cockcroft-Gault formulation)\n11. Written informed consent.\n12. Female subject of childbearing potential should have a negative urine or serum pregnancy within 72 hours prior to receiving the first dose of study medication. If the urine test is positive or cannot be confirmed as negative, a serum pregnancy test will be mandatory.\n13. Female subjects of childbearing potential must be willing to use an adequate method of contraception as outlined in Section - Contraception, for the course of the study through 120 days after the last dose of study medication.\n\n    Note: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.\n14. Male subjects of childbearing potential must agree to use an adequate method of contraception as outlined in Section - Contraception, starting with the first dose of study therapy through 120 days after the last dose of study therapy.\n\nNote: Abstinence is acceptable if this is the usual lifestyle and preferred contraception for the subject.\n\nExclusion Criteria:\n\n1. Adenocarcinoma\n2. Previous thoracic irradiation\n3. Previous systemic chemotherapy\n4. Has received prior therapy with an anti-PD-1 or anti-PD-L1\n5. Synchronous diagnosis of squamous cell carcinoma in the aerodigestive tract, other than esophageal cancer.\n6. Prior malignancy, except for the following:\n\n   1. adequately treated basal cell or squamous cell skin cancer;\n   2. in-situ cervical cancer;\n   3. a \"cured\" malignancy more than 5 years prior to enrollment.\n7. Significant co-morbid disease, which prohibits the conduction of immunochemotherapy, concurrent CRT, or radical surgery, such as active systemic infection, symptomatic cardiac or pulmonary disease, or psychiatric disorders.\n8. Documented myocardial infarction within the 6 months preceding registration (pretreatment ECG evidence of infarct only will not exclude patients). Patients with a history of significant ventricular arrhythmia requiring medication. Patients with a history of 2nd or 3rd degree heart block.\n9. Pre-existing motor or sensory neurotoxicity greater than grade 1.\n10. Patients with prior allergic reactions to drug containing Cremophor, such as teniposide or cyclosporine.\n11. Weight loss \\> 15%.\n12. Dementia or altered mental status that would prohibit the understanding and completion of informed consent.\n13. Estimated life expectancy less than 3 months.\n14. Has a diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other form of immunosuppressive therapy within 7 days prior to the first dose of trial treatment.\n15. Has a known history of active TB (Bacillus Tuberculosis)\n16. Has active autoimmune disease that has required systemic treatment in the past 2 years (i.e. with use of disease modifying agents, corticosteroids or immunosuppressive drugs). Replacement therapy (eg., thyroxine, insulin, or physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is not considered a form of systemic treatment.\n17. Has known history of, or any evidence of active, non-infectious pneumonitis, interstitial lung disease or pulmonary fibrosis.\n18. Is pregnant or breastfeeding, or expecting to conceive or father children within the projected duration of the trial, starting with the pre-screening or screening visit through 120 days after the last dose of trial treatment.\n19. Has a known history of Human Immunodeficiency Virus (HIV) (HIV 1\u002F2 antibodies).\n20. Patients with untreated chronic HBV or chronic HBV carriers whose HBV DNA is ≥500 IU\u002FmL, or patients with active HCV. Patients who are inactive carriers or with treated and stable hepatitis B (detectable B surface antigen and HBV DNA \\\u003C500 IU\u002FmL); patients with non-reactive HCV can be enrolled. Patients with chronic HBV infection need to be treated with anti-HBV agents while receiving immunochemotherapy and chemoradiotherapy according to the local and institutional guidelines.\n21. Has received a live vaccine within 30 days of planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines are live attenuated vaccines, and are not allowed.\n22. Has received organ transplantation.\n23. Has declined esophagectomy.",{"count":117,"type":21},[97],"Effective systemic therapy such as nivolumab as an adjuvant therapy has been demonstrated to improve the outcomes of patients receiving neoadjuvant chemoradiotherapy (CRT) for locoregional esophageal cancer. A more effective systemic therapy with anti-PD-1 or anti-PD-L1 immune checkpoint inhibitors (ICIs) plus cisplatin-based doublet chemotherapy, which has shown with high tumor response rate and improved survivals in patients with late-stage ESCC, may provide crucial benefit to patients with locally advanced disease by improving the systemic control, downstaging the locoregional tumor burden and reducing recurrence and metastasis.\n\nCollectively, the investigators hypothesize that total neoadjuvant therapy (TNT) approach-consisting of induction immunochemotherapy followed by CRT-is a promising strategy to enhance the outcomes for participants with locally advanced esophageal squamous cell carcinoma.",[27,260,261],"Total Neoadjuvant Treatment","Pathological Complete Response",[27],"2026-01-25",{"date":265,"type":36},"2026-01-27",{"date":267,"type":36},"2025-07-23",{"date":269,"type":21},"2028-12",{"name":271,"class":43},"National Taiwan University Hospital",{"id":273,"slug":4,"hasResults":10,"nctId":274,"briefTitle":275,"officialTitle":276,"acronym":4,"eligibilityCriteria":277,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":278,"targetDuration":4,"studyType":22,"phases":280,"briefSummary":281,"conditions":282,"keywords":289,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":292,"lastUpdatePostDateStruct":293,"startDateStruct":295,"completionDateStruct":297,"leadSponsor":299,"locationsCount":44},"100415211","NCT04686682","A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors","A Phase I\u002FIIa, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Evidence of Antitumor Activity of JAB-8263 in Adult Patients With Advanced Malignant Tumors","Inclusion Criteria:\n\n* Subjects must meet all the following criteria in order to be included in the research study:\n\n  1. Subject must be ≥18 years-of-age at the time of signature of the informed consent form (ICF).\n  2. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1.\n  3. Subjects with histologically or cytologically confirmed advanced solid tumors which have progressed despite standard therapy(ies), or are intolerant to standard therapy(ies), or have a tumor for which no standard therapy(ies) exists.\n  4. Subjects with recurrent\u002Frefractory AML according to WHO 2016\n  5. Subjects with life expectancy ≥3 months.\n  6. Patients with solid tumor must have at least one measurable lesion as defined by RECIST v1.1.\n  7. Patients who have sufficient baseline organ function.\n\nExclusion Criteria:\n\n1. History (≤3 years) of cancer that is histologically distinct from the cancer under study.\n2. Known serious allergy to investigational drug or excipients\n3. Active brain or spinal metastases\n4. History of pericarditis or Grade ≥2 pericardial effusion\n5. History of interstitial lung disease.\n6. History of Grade ≥2 active infections within 2 weeks\n7. Known human immunodeficiency virus (HIV) infection\n8. Seropositive for hepatitis B virus (HBV)\n9. Seropositive for hepatitis C virus (HCV), or HCV-RNA viral levels are not detectable.\n10. Any severe and\u002For uncontrolled medical conditions\n11. History of myocardial infarction, unstable angina pectoris, coronary artery bypass graft, or cerebrovascular accident\n12. Impaired cardiac function or clinically significant cardiac diseases\n13. QTcF \\>470 msec at screening\n14. History of medically significant thromboembolic events or bleeding diathesis\n15. Unresolved Grade \\>1 toxicity\n16. History of malignant biliary obstruction\n17. Pregnant or breast-feeding",{"count":279,"type":21},152,[54,97],"This is a Phase 1\u002F2a, first-in-human, open-label study of JAB-8263, this study has two parts: solid tumor dose escalation and expansion study and hematology tumor dose escalation and expansion study.\n\nThese two parts will determine the maximum tolerated dose (MTD), recommended Phase 2 dose (RP2D) and assess the DLT of JAB-8263 in treatment with patients with advanced solid tumors and hematology tumors separately. 30 subjects each will be enrolled.",[214,283,284,27,285,286,287,288],"SCLC","CRPC","Ovarian Carcinoma","AML","MF","Malignant Tumor",[290,291],"BET inhibitor","Bromodomain and Extra-terminal","2026-01-08",{"date":294,"type":36},"2026-01-09",{"date":296,"type":36},"2021-05-07",{"date":298,"type":21},"2028-07",{"name":300,"class":84},"Jacobio Pharmaceuticals Co., Ltd.",{"id":302,"slug":4,"hasResults":10,"nctId":303,"briefTitle":304,"officialTitle":305,"acronym":306,"eligibilityCriteria":307,"healthyVolunteers":308,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":309,"targetDuration":4,"studyType":311,"phases":4,"briefSummary":312,"conditions":313,"keywords":314,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":319,"lastUpdatePostDateStruct":320,"startDateStruct":322,"completionDateStruct":324,"leadSponsor":326,"locationsCount":44},"100613420","NCT07266363","Integrated Cf-miRNA and Exosomal miRNA Signature for Early Detection of Esophageal Squamous Cell Carcinoma","SYNERGY Study: Early Detection Through Integrated Evaluation of Cell-Free and Exosomal microRNAs for Biomarker-Guided Screening of Esophageal Squamous Cell Carcinoma","SYNERGY","Inclusion Criteria:\n\n* Adults age 18 to 90 years\n* Histologically confirmed esophageal squamous cell carcinoma\n* No prior systemic therapy before sample collection\n* For control groups: absence of malignant disease\n\nExclusion Criteria:\n\n* Lack of informed consent\n* Inadequate sample volume or RNA quality\n* Prior cancer within 5 years (except localized cancers)\n* Active systemic inflammation that may alter circulating RNA profiles",true,{"count":310,"type":21},600,"OBSERVATIONAL","Esophageal squamous cell carcinoma (ESCC) remains a highly lethal cancer worldwide, largely due to late diagnosis. Current screening methods such as upper endoscopy are invasive, operator-dependent, and limited in their ability to detect early-stage lesions.\n\nTo address this clinical need, the SYNERGY study seeks to develop a non-invasive, blood-based biomarker assay that integrates cell-free microRNAs (cf-miRNAs) and exosomal microRNAs (exo-miRNAs) to detect ESCC at an early and potentially curable stage.\n\nThis multicenter translational study includes discovery, training, and validation phases using preoperative plasma or serum samples. By combining the tumor specificity of exosomal miRNAs with the systemic sensitivity of cf-miRNAs, SYNERGY aims to construct a robust diagnostic model with high sensitivity and specificity for early ESCC detection.",[27],[315,316,317,318],"Exosomal miRNAs","Cell-free miRNAs","Esophageal squamous cell carcinoma","Liquid biopsy","2025-12-03",{"date":321,"type":36},"2025-12-05",{"date":323,"type":36},"2025-01-15",{"date":325,"type":21},"2026-06-18",{"name":327,"class":43},"City of Hope Medical Center",{"id":329,"slug":4,"hasResults":10,"nctId":330,"briefTitle":331,"officialTitle":332,"acronym":4,"eligibilityCriteria":333,"healthyVolunteers":10,"sex":16,"minAge":334,"maxAge":335,"enrollmentInfo":336,"targetDuration":4,"studyType":22,"phases":338,"briefSummary":339,"conditions":340,"keywords":4,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":343,"lastUpdatePostDateStruct":344,"startDateStruct":346,"completionDateStruct":348,"leadSponsor":349,"locationsCount":44},"100608037","NCT07196345","TAS-102 Plus Radiotherapy in Elderly ESCC","Efficacy and Safety of Trifluridine\u002FTipiracil Combined With Radiotherapy in Elderly Patients With Locally Advanced Esophageal Cancer","Inclusion Criteria:\n\n* Patients must have newly confirmed histologically or cytologically diagnosed esophageal squamous cell carcinoma.\n* Age between 65 and 85 years.\n* Esophageal cancer staged as IIB to IVB according to the 8th edition AJCC staging system (including IVB with supraclavicular or celiac lymph node metastasis, but excluding IVB with other distant metastases).\n* ECOG performance status of 0 or 1.\n* No history of esophageal perforation, active esophageal bleeding, or significant invasion of the trachea or major thoracic blood vessels.\n* No prior anticancer therapy such as radiotherapy or chemotherapy. Adequate bone marrow function: hemoglobin ≥9 g\u002FdL, white blood cells ≥3.0×10⁹\u002FL, neutrophils ≥1.5×10⁹\u002FL, platelets ≥100×10⁹\u002FL.\n* Adequate liver and kidney function: serum creatinine (Scr) ≤1.5×ULN, total bilirubin ≤1.5×ULN, ALT and AST ≤2.5×ULN.\n* No history of interstitial lung disease.\n* Forced expiratory volume (FEV1) ≥0.8 liters.\n* Signed informed consent form before study initiation.\n\nExclusion Criteria:\n\n* Patients with hematogenous metastasis or distant lymph node metastasis (except supraclavicular or celiac lymph node metastasis), multiple esophageal cancer lesions, or malignant pleural\u002Fpericardial effusion.\n* History of radiotherapy, chemotherapy, or surgery targeting the primary tumor or lymph nodes.\n* Tracheoesophageal fistula, invasion of the trachea or main bronchi by the primary tumor, deep esophageal ulcer, or hematemesis.\n* Severe comorbidities such as active infection, cardiovascular disease, or pulmonary disease.\n* History of other malignancies except adequately treated non-melanoma skin cancer.\n* Participation in another clinical trial within the past 30 days.\n* Any other condition deemed by the investigator to preclude participation in the study.","65 Years","85 Years",{"count":337,"type":21},45,[54,97],"This study is a single-arm, multicenter clinical trial evaluating the efficacy and safety of radiotherapy combined with TAS-102 monotherapy in elderly patients with locally advanced esophageal cancer.\n\nTreatment Phase: The treatment phase is divided into a Phase I stage and a Phase II stage. The Phase I stage aims to explore the maximum tolerated dose (MTD) of TAS-102 in elderly esophageal cancer patients. A total of 9 subjects were enrolled, and the dose was escalated from 30 mg\u002Fm² in 5 mg\u002Fm² increments up to 40 mg\u002Fm². The MTD was defined as the highest drug dose at which no dose-limiting toxicity (DLT) was observed in more than 40% of treated patients during the first two weeks of combined radiotherapy and TAS-102 administration. The Phase II stage aims to investigate the efficacy of radiotherapy combined with TAS-102 at the MTD in elderly esophageal cancer patients, with 36 subjects enrolled.\n\nConsolidation Phase: Following the treatment phase, subjects had a 3-4 week rest period. This was followed by consolidation therapy with TAS-102 monotherapy at a dose of 35 mg\u002Fm², administered twice daily on days 1-5 of a 28-day cycle for two cycles.\n\nSubsequently, patients entered the efficacy and safety follow-up phase until the study endpoints were reached or after a full 2-year follow-up period.",[27,341,342],"TAS 102","Radiotherapy","2025-09-21",{"date":345,"type":36},"2025-09-29",{"date":347,"type":21},"2025-09-25",{"date":107,"type":21},{"name":350,"class":43},"Qianfoshan Hospital",{"id":352,"slug":4,"hasResults":10,"nctId":353,"briefTitle":354,"officialTitle":355,"acronym":4,"eligibilityCriteria":356,"healthyVolunteers":10,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":357,"targetDuration":4,"studyType":311,"phases":4,"briefSummary":359,"conditions":360,"keywords":363,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":366,"lastUpdatePostDateStruct":367,"startDateStruct":369,"completionDateStruct":371,"leadSponsor":373,"locationsCount":44},"100596830","NCT07050576","Lymph Node Metastasis in Early Esophageal Squamous Cell Carcinoma","Deep Learning and Radiomics for Prediction of Lymph Node Metastasis in Early-stage Esophageal Squamous Cell Carcinoma","Inclusion Criteria:\n\n* Patients with pathologically confirmed early-stage (T1) ESCC\n* Preoperative contrast-enhanced CT data within 2 weeks before surgery\n* Without any treatment before surgical resection\n\nExclusion Criteria:\n\n* Patients who underwent neoadjuvant therapy or endoscopic treatment\n* Insufficient CT imaging or poor CT quality\n* Incomplete pathology results\n* Presence of metastatic disease",{"count":358,"type":21},500,"This study aims to develop a predictive model using deep learning and radiomics to assess the likelihood of lymph node metastasis in patients with early-stage esophageal squamous cell carcinoma (ESCC). Lymph node metastasis is a critical factor in determining the treatment approach and prognosis for ESCC patients. By analyzing medical imaging data, we hope to create a non-invasive method that can assist doctors in making more accurate treatment decisions. This research could improve patient outcomes by enabling earlier and more tailored interventions.",[27,361,362],"Lymph Node Metastasis","Radiomics",[27,364,365],"Lymph node metastasis","radiomics","2025-06-26",{"date":368,"type":36},"2025-07-03",{"date":370,"type":36},"2024-05-01",{"date":372,"type":21},"2025-11-30",{"name":374,"class":43},"The First Affiliated Hospital of Anhui Medical University",{"id":376,"slug":4,"hasResults":10,"nctId":377,"briefTitle":378,"officialTitle":379,"acronym":4,"eligibilityCriteria":380,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":93,"enrollmentInfo":381,"targetDuration":4,"studyType":22,"phases":383,"briefSummary":384,"conditions":385,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":387,"lastUpdatePostDateStruct":388,"startDateStruct":390,"completionDateStruct":392,"leadSponsor":394,"locationsCount":44},"100553677","NCT06489197","AK112 Combined With Chemotherapy as the First-line Treatment in Advanced Esophageal Squamous Cell Carcinoma Patients","Ivonescimab(AK112) Combined With Chemotherapy as the First-line Treatment in Patients With Advanced Esophageal Squamous Cell Carcinoma (ESCC): A Single Arm , Phase II Trial","Inclusion Criteria:\n\n1. Signed the informed consent；\n2. Male or female patients ≥18 and ≤ 75 years old;\n3. ECOG physical status score is 0 or 1;\n4. Patients with non resectable or metastatic advanced ESCC confirmed by pathological ocytological examination;\n5. No previous systemic treatment;\n6. Expected survival time ≥ 3 months;\n7. Patients must have at least one measurable metastatic lesion according to RECIST version 1.1;\n8. Normal organ function:\n\n   1. Hematology :Absolute neutrophil count (ANC) ≥ 1.5 × 109\u002FL (1500\u002Fmm3); Platelet count ≥ 100 × 109\u002FL (100000\u002Fmm3); Hemoglobin ≥ 90g\u002FL;\n   2. Kidney:The calculated value of creatinine clearance rate (CrCl) is ≥ 50 mL\u002Fmin;Normal urine routine, urine protein\\\u003C2+or 24-hour (h) urine protein quantification\\\u003C1.0 g;\n   3. Liver:Total serum bilirubin (TBiL) ≤ 1.5 × ULN;AST and ALT ≤ 2.5 × ULN; For subjects with liver metastasis, AST and ALT can be ≤ 5 × ULN;Serum albumin (ALB) ≥ 30g\u002FL;\n   4. Normal coagulation function, international standardized ratio (INR) ≤ 1.5 x ULN, prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤ 1.5 x ULN;\n9. Women of childbearing age must undergo a pregnancy test (serum or urine) with a negative result within 14 days before enrollment, and voluntarily use appropriate methods of contraception during the observation period and within 8 weeks after the last administration of the study drug; For males, surgical sterilization or agreement to use appropriate methods of contraception during observation and within 8 weeks after the last administration of study medication should be considered;\n10. Comply with the scheduled visits, treatment plans, laboratory tests, and other requirements of the study;\n\nExclusion Criteria:\n\n1. Local advanced esophageal squamous cell carcinoma that can be curative through surgery or potentially cured through radiation therapy;\n2. Suffering from other malignant tumors within the 5 years prior to enrollment. Patients with other malignant tumors that have been cured by local treatment, such as basal or cutaneous squamous cell carcinoma, superficial bladder cancer, cervical or breast cancer in situ, are not excluded;\n3. Active bleeding signs of the lesion are displayed under endoscopy;\n4. Currently participating in intervention clinical research treatment, or having received other research drugs or used research instruments within 4 weeks before the first administration;\n5. Receiving immunotherapy in the past, including immune checkpoint inhibitors (such as anti-PD-1\u002FL1 antibodies, anti-CTLA-4 antibodies, anti-TIGIT antibodies, anti-LAG3 antibodies, etc.), immune checkpoint agonists (such as ICOS, CD40, CD137, GITR, OX40 antibodies, etc.), immune cell therapy, or any other treatment targeting the immune mechanism of tumors;\n6. Received systemic non-specific immunomodulatory therapy (such as interleukin, interferon, thymosin, etc.) within 2 weeks before the first administration;\n7. Active autoimmune diseases that require systemic treatment (such as the use of disease relieving drugs, glucocorticoids, or immunosuppressants) have occurred within 2 years prior to the first administration.\n8. The study is currently undergoing systemic glucocorticoid therapy (excluding local glucocorticoids through nasal spray, inhalation, or other routes) or any other form of immunosuppressive therapy within 7 days prior to the first administration; Note: Physiological doses of glucocorticoids (≤ 10 mg\u002Fday of prednisone or equivalent) are allowed to be used;\n9. Clinically significant gastrointestinal obstruction, gastrointestinal perforation, intra-abdominal abscess, fistula formation, etc. occur within 6 months before the first administration;\n10. Active, uncontrolled, or recurrent inflammatory gastrointestinal diseases (such as Crohn's disease, ulcerative colitis, radiation enteritis, hemorrhagic enteritis, chronic diarrhea, etc.);\n11. Previous history of myocarditis, cardiomyopathy, and malignant arrhythmia. Unstable angina, myocardial infarction, congestive heart failure (classified as grade 2 or above according to the New York Heart Association functional classification) or vascular disease (such as aortic aneurysm with a risk of rupture) that requires hospitalization within 12 months prior to the first administration, or other cardiac damage that may affect the safety evaluation of the investigational drug (such as poorly controlled arrhythmias, myocardial ischemia);\n12. Any arterial thromboembolism events, NCI CTCAE 5.0 grade 3 or above venous thromboembolism events, transient ischemic attacks, cerebrovascular accidents, hypertensive crises, or hypertensive encephalopathy occurred within 6 months prior to the first administration; Currently, there is hypertension and after treatment with oral antihypertensive drugs, the systolic blood pressure is ≥ 160mmHg or the diastolic blood pressure is ≥ 100mmHg;\n13. Severe infections occurring within 4 weeks prior to the first administration, including but not limited to comorbidities requiring hospitalization, sepsis, or severe pneumonia; Active infections that have received systemic anti infective treatment within 2 weeks prior to the first administration (excluding antiviral treatment for hepatitis B or C);\n14. Subjects with active hepatitis B are required to receive anti hepatitis B virus treatment during the study treatment; Active hepatitis C subjects (HCV antibody positive and HCV RNA levels above the detection limit);\n15. Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation;\n16. If the toxicity of previous anti-tumor treatments has not improved, it is defined as the toxicity has not returned to level 0 or 1 of NCI CTCAE 5.0, or the level specified in the inclusion\u002Fexclusion criteria, except for hair loss;\n17. Known to be allergic to any component of any investigational drug; Known medical history of severe hypersensitivity reactions to other monoclonal antibodies;\n18. If a live vaccine or attenuated live vaccine is administered within 30 days prior to the first administration, or if a live vaccine or attenuated live vaccine is planned to be administered during the study period, the use of inactivated vaccines is allowed;\n19. Known history of mental illness, drug abuse, alcohol or drug abuse;\n20. Pregnant or lactating women;\n21. Those who have undergone major surgical procedures or experienced severe trauma within 30 days prior to the first administration, or those who have planned major surgical procedures within 30 days after the first administration (as determined by the investigator); Minor local surgeries were performed within 3 days prior to the first administration (excluding peripheral venous puncture, central venous catheterization, and intravenous infusion port implantation);\n22. During the screening period, imaging showed significant necrosis and cavities in the tumor, and the researchers determined that entering the study would pose a risk of bleeding; Tumors invade important blood vessels and organs; Tumor mediastinal lymph node metastasis invading the trachea, main bronchus, or at risk of developing esophagotracheal fistula or esophagopleural fistula;\n23. Have a history of severe bleeding tendency or coagulation dysfunction; There are significant clinically significant bleeding symptoms within one month prior to the first administration; Patients who have previously or currently require long-term therapeutic anticoagulation therapy (such as atrial fibrillation patients who meet CHADS2 score ≥ 2);\n24. The researcher believes that there are other potential risks that are not suitable for participation in this study;",{"count":382,"type":21},30,[97],"This is a single arm，phase 2 study evaluating the safety and efficacy of Ivonescimab(AK112) combined with chemotherapy in the treatment of advanced esophageal squamous cell carcinoma (ESCC). In this study, patients with advanced esophageal squamous cell carcinoma who had not received any systematic treatment in the past will be enrolled.\n\nThe research will be conducted in two stages. In the first part, 6 patients were enrolled in the group. After the last subject in the group completed at least 21 days of observation after the first medication, the researchers will conduct a preliminary safety and effectiveness assessment. If the safety and tolerability are good, it will enter the second expansion part till the study enrolled 30 patients. Patients who met the inclusion criteria were treated with AK112 (20mg\u002Fkg, intravenous infusion, d1, Q3W) in combination with albumin paclitaxel (220mg\u002Fm2, intravenous infusion, d1, Q3W) and cisplatin (75mg\u002Fm2, intravenous infusion, d1, Q3W), of which the maximum treatment time of chemotherapy was up to six cycles, and the maximum treatment time of AK112 was 24 months. Patients received regular and periodic reviews, with imaging evaluations every 6 weeks.",[27,386],"Advanced Esophageal Squamous Cell Carcinoma","2025-01-20",{"date":389,"type":36},"2025-01-22",{"date":391,"type":36},"2024-11-16",{"date":393,"type":21},"2027-08-30",{"name":109,"class":43},{"id":396,"slug":4,"hasResults":10,"nctId":397,"briefTitle":398,"officialTitle":399,"acronym":400,"eligibilityCriteria":401,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":402,"targetDuration":4,"studyType":311,"phases":4,"briefSummary":403,"conditions":404,"keywords":405,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":407,"lastUpdatePostDateStruct":408,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":44},"100569780","NCT06698692","Trilaciclib for the Prevention of Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell Carcinoma","Real-world Assessment of Trilaciclib for the Prevention of Chemoradiotherapy-Induced Myelosuppression in Esophageal Squamous Cell Carcinoma","COSELA","Inclusion Criteria:\n\n* age ≥18 years;\n* pathological diagnosis of esophageal squamous cell carcinoma;\n* failure to undergo surgical treatment;\n* completion of definitive chemoradiotherapy or chemoradiotherapy combined with immunotherapy.\n\nExclusion Criteria:\n\n* history of other malignant tumors;\n* difficulty in follow-up;\n* insufficient clinical information.",{"count":95,"type":21},"Clinical data of patients with synchronous radiotherapy for esophageal cancer in the Department of Radiology of Jiangsu Provincial People's Hospital were collected. Patients were divided into trilaciclib group (34 cases) and control group (169 cases) based on whether trilaciclib was used or not. Patients in the trilaciclib group were given trilaciclib before each chemotherapy treatment. Propensity score matching (PSM) was used to balance the baseline characteristics between the two groups on a 1:1 ratio. After pairing, the rates of bone marrow suppression and other adverse events were compared between the two groups.",[27],[406],"trilaciclib","2024-11-19",{"date":409,"type":36},"2024-11-21",{"date":411,"type":36},"2024-04-02",{"date":413,"type":21},"2025-04-02",{"name":415,"class":43},"The First Affiliated Hospital with Nanjing Medical University",{"id":417,"slug":4,"hasResults":10,"nctId":418,"briefTitle":419,"officialTitle":420,"acronym":4,"eligibilityCriteria":421,"healthyVolunteers":10,"sex":16,"minAge":17,"maxAge":93,"enrollmentInfo":422,"targetDuration":4,"studyType":22,"phases":424,"briefSummary":425,"conditions":426,"keywords":430,"overallStatus":100,"whyStopped":4,"lastUpdateSubmitDate":433,"lastUpdatePostDateStruct":434,"startDateStruct":436,"completionDateStruct":438,"leadSponsor":440,"locationsCount":44},"100556913","NCT06531291","Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation","Surufatinib Combined With Serplulimab and Standard Chemotherapy as First-line Treatment in Advanced Solid Tumors With Neuroendocrine Differentiation: A Single-arm, Multi-cohort, Open-label, Single-center, Prospective, Exploratory Clinical Study","Inclusion Criteria:\n\n* Histopathologically confirmed locally advanced or metastatic unresectable ESCC, BTC, PC or GC with an abnormal NED or NE phenotype (without neuroendocrine morphologic features and positive immunohistochemical expression of at least one neuroendocrine marker (CgA, Syn));\n* Have at least one measurable lesion according to RECIST v1.1;\n* ECOG performance status: 0-1;\n* No previous systemic therapy;\n* Urine protein\\\u003C ++ . If Urine protein ≥ ++ ,the amount of urine protein in 24 hours ≤1.0g;\n* Expected survival time \\> 3 months;\n\nExclusion Criteria:\n\n* Have uncontrolled hypertension, defined as systolic blood pressure \\>150 mmHg or diastolic blood pressure \\>90 mm Hg, while under anti-hypertension treatment;\n* With active bleeding or bleeding tendency;\n* Severe history of cardiovascular and cerebrovascular diseases;\n* Other malignancies diagnosed within the previous 5 years, except basal cell carcinoma or cervical carcinoma in situ after radical resection.",{"count":423,"type":21},80,[97],"Currently, there are no standard treatment and relevant exploration for solid tumors patients with NED. The study aims to explore the efficacy and safety of surufatinib combined with serplulimab and standard chemotherapy in the treatment ofadvanced solid tumors with NED, in order to provide a new treatment option for advanced solid tumors patients with NED.",[27,427,428,429],"Biliary Tract Cancer","Gastric Cancer","Pancreas Cancer",[431,432],"surufatinib","Neuroendocrine Differentiation","2024-07-28",{"date":435,"type":36},"2024-07-31",{"date":437,"type":21},"2024-08-10",{"date":439,"type":21},"2027-08-09",{"name":441,"class":43},"RenJi Hospital",""]